Physician profile
Roberto Navarrette
NPI 1659340602
$2,433.50
in general payments reported to CMS, 2019-2025
17 companies · $570 in 2025
The $570 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $37.90 · 2023: $382 · 2024: $1,022 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $786.43 | 2021-2025 | Aveir, Merlin@Home, Gallant |
| Medtronic, INC. | $327.87 | 2021-2025 | Symplicity G3, Corevalve Evolut R |
| E.R. Squibb & Sons, L.L.C. | $228.05 | 2021-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $207.32 | 2021-2025 | |
| Abiomed | $204.71 | 2024-2025 | Impella |
| Shockwave Medical, INC | $178.42 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.40 | 2021-2024 | Jardiance |
| Amgen INC. | $95.32 | 2021-2025 | Repatha, Repatha |
| Kiniksa Pharmaceuticals International, Plc | $61.38 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $37.93 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.47 | 2021-2025 | Lifevest |
| Pfizer INC. | $28.07 | 2024-2025 | |
| Baxter Healthcare | $24.73 | 2025 | Perclot |
| Lexicon Pharmaceuticals, INC. | $16.75 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $15.71 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $12.74 | 2021 | |
| Esperion Therapeutics, INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Navarrette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.